• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • Cardiology, Diabetes & Nephrology – USA
    • Hatter Horizon Series
    • The 18th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Cell Therapy
    • Cell Therapy at the Limits 2021
  • Oncology
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
      • UCL Frontiers of Oncology 2019
        • Haematology
        • Melanoma
        • Urology
        • Women’s Health
        • Lung Cancer
        • Gastrointestinal Oncology
        • Paediatric Oncology
        • Supporters
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2021
    • Multiple Sclerosis Nurses at the Limits 2021
    • Previous Events
      • Multiple Sclerosis Nurses at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2019
      • MSATL 2018: Introduction
      • MSATL 2017: Introduction
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Supporters
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis at the Limits 2018
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series
      • Horizon GP Programme 2019
      • Hatter Horizon Series 2019
      • Hatter Horizon Series 2018
      • Hatter Horizon Series 2017
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017

Professor Dr Emile Voest

Emile Voest is professor of Medical Oncology and serves as Medical Director on the executive board of the Netherlands Cancer Institute in Amsterdam.

He also serves as chair of the Center for Personalized Cancer Treatment (a national program involving academic cancer centers and teaching hospitals), as chair of the scientific council of the Pediatric Oncology Foundation (KiKa) and as medical director on the board of the HUB Foundation for Organoid Technology and Stemcell technology.

His translational research has focused on improving systemic treatment for patients with cancer. This includes the clinical development of targeted agents, discovery and validation of biomarkers with emphasis on genetics and tumor organoids, and identification of new targets of treatment to overcome chemoresistance.

Dr Voest was registered as a medical doctor in 1985. He became board certified as an internist July 1993, and as a medical oncologist in January 1995. He completed his PhD program on the enhancement of the efficacy of anthracyclines by modulation of iron metabolism in tumor cells June 1993 (cum laude). In 1994 and 1995 he was a postdoctoral fellow of the Dutch Cancer Society. As a postdoctoral fellow he joined the laboratory of Dr. Judah Folkman, Children’s Hospital, Harvard Medical School, Boston and worked on endogenous inhibitors of angiogenesis. Thereafter he worked at the Netherlands Cancer Institute in Amsterdam on high dose chemotherapy. In November 1999 he became a full professor in Medical Oncology in Utrecht. He currently serves in a variety of scientific committees and advisory boards. He has several patents to his name in the field of angiogenesis and biomarkers. In 2011, he spend a 6 months sabbatical at UCSD on bioinformatics and systems biology. Until April 2014, he was chair of the scientific council of the Dutch Cancer Society (KWF).

He co-authored some 200 manuscripts that together have been cited almost 7,000 times.

Dr Voest serves as one of the Team Leaders in the Stand up to Cancer International Translational Research Grant “Prospective Use of DNA-guided Personalized Cancer Treatment”.

« Professor Jan Schellens
Dr Mark R Philips »

Cardiology, Diabetes & Nephrology at the Limits Canada
Wednesday, 3 & Thursday, 4 March 2021, Virtual Meeting

Cardiology, Diabetes & Nephrology at the Limits 2021
Monday, 12 - Tuesday, 13 April 2021, London, UK

The 18th Malvern Diabetic Foot Conference
Wednesday, 12 – Friday, 14 May 2021, Malvern, UK

Hatter Horizon GP Meeting
Wednesday, 19 May 2021
London, UK

Hatter Horizon Series
Friday, 21 May 2021
London, UK

Multiple Sclerosis Nurses
at the Limits

Friday, 4 & Saturday, 5 June 2021, London, UK

Multiple Sclerosis at the Limits
Thursday, 24 & Friday, 25 June 2021, London, UK

Cardiology, Diabetes & Nephrology at the Limits Brazil
Friday, 16 - Saturday, 17 July 2021, São Paulo, Brazil

Cell Therapy at the Limits 2021
Wednesday, 21 & Thursday, 22 July 2021, London, UK

Policy links

  • Medical Disclaimer
  • Disclosure
  • E-mail Policy
  • Privacy Policy
  • Anti-spam Policy
  • Disclaimer
  • External Links Policy
  • Terms of use
  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2020 At the Limits Ltd.
This site uses cookies More info